Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × donafenib × Head & Neck × Clear all

Phase

Phase 2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Gastrointestinal 1 Endocrine 1

Conditions

Differentiated Thyroid Cancer 1

Interventions

Cisplatin 124 Radiotherapy 58 Fluorouracil 43 Radiotherapy, Intensity-Modulated 41 Docetaxel 35 Gemcitabine 33 Cetuximab 31 Carboplatin 25 pembrolizumab 22 Capecitabine 20 Drug Therapy 16 Paclitaxel 14 toripalimab 13 Nivolumab 10 Surgical Procedures, Operative 9 nimotuzumab 8 camrelizumab 8 Methotrexate 8 Magnetic Resonance Spectroscopy 8 Chemoradiotherapy 8 nedaplatin 7 Chemotherapy, Adjuvant 7 tislelizumab 6 Standard of Care 6 Specimen Handling 6 Radiation 6 Platinum 6 Neoadjuvant Therapy 6 Iodine-131 6 Induction Chemotherapy 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡